Log in
NASDAQ:APTO

Aptose Biosciences Stock Forecast, Price & News

$6.28
+0.15 (+2.45 %)
(As of 11/27/2020 12:00 AM ET)
Add
Compare
Today's Range
$6.16
Now: $6.28
$6.40
50-Day Range
$4.38
MA: $5.38
$6.28
52-Week Range
$2.43
Now: $6.28
$9.25
Volume397,268 shs
Average Volume947,363 shs
Market Capitalization$558.05 million
P/E RatioN/A
Dividend YieldN/A
Beta1.52
Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.
Read More
Aptose Biosciences logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.41 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:APTO
CUSIPN/A
Phone858-926-2730
Employees31

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$1.45 per share

Profitability

Net Income$-26,280,000.00

Miscellaneous

Market Cap$558.05 million
Next Earnings Date3/9/2021 (Estimated)
OptionableOptionable
$6.28
+0.15 (+2.45 %)
(As of 11/27/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive APTO News and Ratings via Email

Sign-up to receive the latest news and ratings for APTO and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Aptose Biosciences (NASDAQ:APTO) Frequently Asked Questions

How has Aptose Biosciences' stock been impacted by Coronavirus?

Aptose Biosciences' stock was trading at $5.84 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, APTO stock has increased by 7.5% and is now trading at $6.28.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Aptose Biosciences?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aptose Biosciences in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Aptose Biosciences
.

What stocks does MarketBeat like better than Aptose Biosciences?

Wall Street analysts have given Aptose Biosciences a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Aptose Biosciences wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Aptose Biosciences' next earnings date?

Aptose Biosciences is scheduled to release its next quarterly earnings announcement on Tuesday, March 9th 2021.
View our earnings forecast for Aptose Biosciences
.

How were Aptose Biosciences' earnings last quarter?

Aptose Biosciences Inc. (NASDAQ:APTO) posted its earnings results on Sunday, November, 15th. The biotechnology company reported ($0.15) earnings per share for the quarter, topping the consensus estimate of ($0.18) by $0.03.
View Aptose Biosciences' earnings history
.

What price target have analysts set for APTO?

7 analysts have issued 1-year price objectives for Aptose Biosciences' stock. Their forecasts range from $9.00 to $16.00. On average, they expect Aptose Biosciences' share price to reach $11.29 in the next year. This suggests a possible upside of 79.7% from the stock's current price.
View analysts' price targets for Aptose Biosciences
.

Are investors shorting Aptose Biosciences?

Aptose Biosciences saw a increase in short interest during the month of October. As of October 30th, there was short interest totaling 2,120,000 shares, an increase of 12.8% from the October 15th total of 1,880,000 shares. Based on an average trading volume of 862,500 shares, the short-interest ratio is presently 2.5 days. Currently, 2.6% of the shares of the stock are short sold.
View Aptose Biosciences' Short Interest
.

Who are some of Aptose Biosciences' key competitors?

What other stocks do shareholders of Aptose Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aptose Biosciences investors own include Aurinia Pharmaceuticals (AUPH), Arch Therapeutics (ARTH), Aurora Cannabis (ACB), NVIDIA (NVDA), Advanced Micro Devices (AMD), Anavex Life Sciences (AVXL), CymaBay Therapeutics (CBAY), Cisco Systems (CSCO), Micron Technology (MU) and SCYNEXIS (SCYX).

Who are Aptose Biosciences' key executives?

Aptose Biosciences' management team includes the following people:
  • Dr. William G. Rice Ph.D., Chairman, Pres & CEO (Age 59)
  • Mr. Gregory K. Chow CPA, MBA, BA, Sr. VP, CFO & Principal Accounting Officer (Age 45)
  • Mr. Ernest Kitt B.S., M.S, VP of Devel. & Technical Operations
  • Dr. Stephen B. Howell, Chief Medical Officer (Age 73)
  • Mr. Peter Murray, Director of Clinical Devel.

What is Aptose Biosciences' stock symbol?

Aptose Biosciences trades on the NASDAQ under the ticker symbol "APTO."

Who are Aptose Biosciences' major shareholders?

Aptose Biosciences' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Consonance Capital Management LP (9.00%), Nantahala Capital Management LLC (7.75%), Corriente Advisors LLC (3.86%), Point72 Asset Management L.P. (2.33%), Polar Capital LLP (2.03%) and Polar Capital LLP (2.03%). Company insiders that own Aptose Biosciences stock include Erich Platzer, Gregory K Chow, Jotin Marango, Warren Whitehead and William G Rice.
View institutional ownership trends for Aptose Biosciences
.

Which major investors are buying Aptose Biosciences stock?

APTO stock was purchased by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Consonance Capital Management LP, Nantahala Capital Management LLC, Sanders Morris Harris LLC, Corriente Advisors LLC, Polar Capital LLP, Polar Capital LLP, and Voss Capital LLC. Company insiders that have bought Aptose Biosciences stock in the last two years include Gregory K Chow, and William G Rice.
View insider buying and selling activity for Aptose Biosciences
.

How do I buy shares of Aptose Biosciences?

Shares of APTO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Aptose Biosciences' stock price today?

One share of APTO stock can currently be purchased for approximately $6.28.

How big of a company is Aptose Biosciences?

Aptose Biosciences has a market capitalization of $558.05 million. The biotechnology company earns $-26,280,000.00 in net income (profit) each year or ($0.52) on an earnings per share basis. Aptose Biosciences employs 31 workers across the globe.

What is Aptose Biosciences' official website?

The official website for Aptose Biosciences is www.aptose.com.

How can I contact Aptose Biosciences?

Aptose Biosciences' mailing address is 251 CONSUMERS ROAD SUITE 1105, TORONTO A6, M2J 4R3. The biotechnology company can be reached via phone at 858-926-2730 or via email at [email protected]tose.com.

This page was last updated on 11/28/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.